Table 2.
Median 12-item Short Form Survey (SF-12) component scores by patients’ characteristic variables.
| Variable | n | Score of PCS-12 Median (min–max) | p-Value | Score of MCS-12 Median (max–min) | p-Value |
|---|---|---|---|---|---|
| All the sample | 20 | 53.6 (43.7–60.6) | 28.6 (19.6–37.9) | ||
| Age | 0.06 | 0.018 | |||
| Under 60 | 4 | 48.8 (44.5–53.4) | 31.9 (29.9–35.2) | ||
| Over 60 | 16 | 56.2 (43.7–60.6) | 27.4 (19.6–37.97) | ||
| Gender | 0.70 | 0.22 | |||
| Male | 8 | 54.02 (43.7–60.3) | 28.789 (26.2–37.97) | ||
| Female | 12 | 54.5 (44.5–60.6) | 27.4 (19.6–35.2) | ||
| Marital status | 0.71 | 0.58 | |||
| Single | 5 | 54.7 (43.8–60.1) | 27.5 (25.4–37.97) | ||
| Married | 14 | 54.5 (44.5–60.6) | 27.7 (19.6–35.2) | ||
| Not declared | 1 | 53.4 | 30.8 | ||
| Tumor | 0.28 | 0.68 | |||
| Cancer | 8 | 57.4 (50.2–60.1) | 27.7 (24.4–29.7) | ||
| Cancer with bone metastasis | 12 | 52.96 (44.5–60.6) | 28.6 (19.6–37.97) | ||
| Anti-resorptive medication timing | 0.86 | 0.73 | |||
| Past | 15 | 53.5 (43.7–60.6) | 27.9 (19.6–37.97) | ||
| Current | 5 | 57.1 (45–60.1) | 27.4 (25.4–35.2) | ||
| Active principle | 0.57 | 0.54 | |||
| Zoledronic acid | 9 | 54.7 (43.7–60.6) | 27.5 (19.6–37.97) | ||
| Clodronic acid | 1 | 57.1 | 28.8 | ||
| Alendronic acid | 1 | 60.1 | 25.4 | ||
| Denosumab (one dose every month) | 3 | 57.8 (50.8–60.3) | 27.9 (26.5–29.8) | ||
| Adalimumab | 1 | 53.5 | 23.6 | ||
| Combination | 5 | 50.2 (45–59.4) | 29.7 (26.3–35.2) | ||
| Method of administration | 0.38 | 0.38 | |||
| I.V | 11 | 53.4 (43.7–60.6) | 27.5 (19.6–37.97) | ||
| I.M/S.C | 5 | 57.1 (50.8–60.3) | 27.9 (23.6–29.8) | ||
| Oral | 1 | 60.1 | 25.4 | ||
| Association | 3 | 52.6 (45–59.4) | 32.99 (27.4–35.2) | ||
| Anti-resorptive medications duration | 0.25 | 0.45 | |||
| <3 years | 8 | 57.1 (50.2–60.3) | 29.3 (26.6–37.97) | ||
| >3 years | 12 | 51.7 (47.7–60.6) | 28.1 (19.6–35.2) | ||
| I.V < 8 infusions | 2 | 57.4 (55.4–59.4) | 25.9 (24.4–27.4) | ||
| I.V + 8 infusions | 12 | 51.4 (43.7–60.6) | 29.8 (19.6–37.97) | ||
| MRONJ stage | 0.85 | 0.15 | |||
| 0 | 6 | 53.4 (46.8–60.1) | 27.5 (23.6–30.8) | ||
| I | 2 | 51.4 (45–57.7) | 31.4 (27.5–35.2) | ||
| II | 11 | 55.4 (43.7–60.6) | 27.4 (19.6–34.5) | ||
| III | 1 | 54.7 | 37.97 | ||
| Localization | 0.47 | 1.00 | |||
| Maxilla | 3 | 54.1 (43.7–60.3) | 27.438 (23.6–37.97) | ||
| Mandible | 12 | 57.8 (45–60.6) | 27.9 (19.6–35.2) | ||
| Both | 5 | 54.3 (46.8–60.1) | 28.2 (25.4–30.8) | ||